Hong Kong Aerospace & Defense Stock News

It looks like Computer And Technologies Holdings Limited ( HKG:46 ) is about to go ex-dividend in the next four days...

BaTeLab Co., Ltd. ( HKG:2149 ) missed earnings with its latest yearly results, disappointing overly-optimistic...

Greentown Service Group Co. Ltd.'s ( HKG:2869 ) strong earnings report was rewarded with a positive stock price move...

It's been a good week for Binjiang Service Group Co. Ltd. ( HKG:3316 ) shareholders, because the company has just...

Soft earnings didn't appear to concern Wynn Macau, Limited's ( HKG:1128 ) shareholders over the last week. Our analysis...

China XLX Fertiliser Ltd. ( HKG:1866 ), is not the largest company out there, but it saw a significant share price rise...

One of the biggest stories of last week was how Pop Mart International Group Limited ( HKG:9992 ) shares plunged 29% in...

There's been a notable change in appetite for Kuaishou Technology ( HKG:1024 ) shares in the week since its annual...

Robosense Technology Co., Ltd ( HKG:2498 ) came out with its annual results last week, and we wanted to see how the...

The United Laboratories International Holdings Limited ( HKG:3933 ) missed earnings with its latest full-year results...

As you might know, Huaneng Power International, Inc. ( HKG:902 ) last week released its latest yearly, and things did...

The full-year results for Kerry Properties Limited ( HKG:683 ) were released last week, making it a good time to...

BYD stock overview BYD (SEHK:1211) has drawn fresh attention after recent share price moves, with the stock up over the past week, month and past 3 months, prompting investors to reassess its current valuation. See our latest analysis for BYD. At around HK$106.5, recent gains, including a 3.70% 1 day and 7.85% 30 day share price return, contrast with a 1 year total shareholder return of around a 20.59% decline. However, 3 and 5 year total shareholder returns of 43.41% and 85.91% suggest...

ETS Group Limited ( HKG:8031 ) shareholders (or potential shareholders) will be happy to see that the Head of Corporate...

Shanghai Bao Pharmaceuticals (SEHK:2659) has reported its FY 2025 first half with revenue of C¥42.0 million and a basic EPS loss of C¥3.18, while trailing twelve month figures show revenue of C¥49.2 million against a net loss of C¥395.3 million and EPS of C¥1.36 in the red. Over the past few reporting halves, revenue has moved from C¥1.49 million in 2024 H1 to C¥4.67 million in 2024 H2 and then to C¥42.0 million in 2025 H1, as EPS stayed firmly negative across all periods. This sets up a...

Da Ming International Holdings (SEHK:1090) has opened FY 2025 with first half revenue of CNY 21.2b and basic EPS of CNY 0.01, while the trailing twelve months still reflect a loss with basic EPS at CNY 0.03 on revenue of CNY 44.2b and net loss excluding extra items of CNY 35.6m. Over the past three reported half year periods, revenue has moved from CNY 22.8b in 1H 2024 to CNY 23.7b in 2H 2024 and then to CNY 21.2b in 1H 2025, with net income excluding extra items shifting from CNY 4.4m to a...

One of the biggest stories of last week was how Adicon Holdings Limited ( HKG:9860 ) shares plunged 21% in the week...

Last week, you might have seen that Xiaocaiyuan International Holding Ltd. ( HKG:999 ) released its annual result to...

It's been a good week for Beijing Enterprises Urban Resources Group Limited ( HKG:3718 ) shareholders, because the...

It's shaping up to be a tough period for Dongyue Group Limited ( HKG:189 ), which a week ago released some...

Chervon Holdings Limited ( HKG:2285 ) missed earnings with its latest full-year results, disappointing...

It's been a sad week for DPC Dash Ltd ( HKG:1405 ), who've watched their investment drop 14% to HK$51.75 in the week...

Hung Hing Printing Group (SEHK:450) has reported FY 2025 first half revenue of HK$935.4 million with a basic EPS loss of HK$0.053763, while trailing twelve month revenue sits at about HK$2.0 billion against a basic EPS loss of HK$0.087. Over recent periods the company has seen revenue move from HK$1,095.7 million in 2024 H1 to HK$1,099.1 million in 2024 H2, as net income shifted from a loss of HK$4.5 million to a loss of HK$38.9 million and then to a loss of HK$48.8 million in 2025 H1. This...

Keymed Biosciences (SEHK:2162) has just posted FY 2025 first half revenue of C¥498.8 million with a basic EPS loss of C¥0.30 per share, while trailing twelve month figures show revenue of C¥716.3 million and a basic EPS loss of C¥1.91. Over recent reporting halves, the company has seen revenue move from C¥54.7 million in 1H 2024 to C¥373.4 million in 2H 2024 and then to C¥498.8 million in 1H 2025, alongside basic EPS losses of C¥1.29, C¥0.68 and C¥0.30 respectively. These figures place the...